As he is currently filing patents, Engelmayr cannot yet go into detail on his scaffolding technology, but told us he was utilizing advanced manufacturing and automation and biomechanics to mimic muscle tissues in a process that is “scalable, cost effective, and designed for regulatory approval from day one. My target is to do my first FDA submission by Q2 of 2024 and maybe sooner.”
Source: Cultivated meat startup Myodenovo emerges from stealth
[…] Cultivated meat startup Myodenovo emerges from stealth – May 5, 2023 […]